Want to see LH full AI Analyst Report?
LH Stock Chart & Stats
$270.68
-$1.45(-0.62%)
At close: 4:00 PM EST
$270.68
-$1.45(-0.62%)
Day’s Range― - ―
52-Week Range$244.52 - $298.46
Previous CloseN/A
Volume103.18K
Average Volume (3M)622.61K
Market Cap
$23.08B
Enterprise Value$27.54B
Total Cash (Recent Filing)$981.10M
Total Debt (Recent Filing)$7.24B
Price to Earnings (P/E)25.6
Beta0.28
Next Earnings
Jul 30, 2026EPS Estimate
4.78Next Dividend Ex-DateN/A
Dividend Yield0.99%
Share Statistics
EPS (TTM)11.37
Shares Outstanding82,000,000
10 Day Avg. Volume596,689
30 Day Avg. Volume622,606
Financial Highlights & Ratios
PEG Ratio1.28
Price to Book (P/B)2.42
Price to Sales (P/S)1.50
P/FCF Ratio17.31
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue1.95
Enterprise Value/Gross Profit7.01
Enterprise Value/Ebitda13.35
Forecast
1Y Price Target
$313.43Price Target Upside15.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)18.02
Revenue Forecast (FY)$14.70B
Bulls Say, Bears Say
Bulls Say
Diversified Business ModelLabcorp’s two‑pillar model (Diagnostics + Drug Development) provides durable revenue diversification across fee‑for‑service testing and CRO contracts. This reduces single‑market exposure, supports cross‑sell of specialty assays, and steadies demand cycles, aiding long‑term cash generation and resilience.
Healthy BLS Backlog And Book‑to‑billA multi‑billion dollar BLS backlog with a book‑to‑bill above 1 gives predictable near‑term revenue and workload visibility. This supports capacity planning, margin improvement in Central Labs, and multi‑period cash flow conversion, underpinning durable revenue realization from drug development contracts.
Improving Cash Generation & FCFRising operating cash flow and stronger free cash flow provide sustainable funding for M&A, buybacks, dividends and capex. Improved cash conversion supports capital returns and strategic investments while cushioning execution risk versus peers dependent on external financing.
Bears Say
Regulatory & Reimbursement UncertaintyPolicy shifts like CRUSH or PAMA/RESULTS Act can structurally alter reimbursement rates and access for diagnostic testing. Such regulatory outcomes can compress realized prices for routine and specialty assays, erode margins and require sustained commercial and product adjustments to protect revenue.
Elevated Leverage And Refinancing ActivityMaterial outstanding debt and recent prefunding point to active refinancing and constrained flexibility. If cash generation slows or margins deteriorate, debt servicing and upcoming maturities could limit investable cash, increase interest expense risk, and hamper opportunistic M&A or buybacks.
Earnings Cash‑conversion GapA persistent gap where operating cash falls well below reported net income signals timing, working capital or non‑cash item risks to earnings quality. This undermines confidence that accounting profits will reliably convert to cash, potentially constraining sustainable capital returns and balance‑sheet flexibility.
Labcorp Holdings News
LH FAQ
What was Labcorp Holdings Inc.’s price range in the past 12 months?
Labcorp Holdings Inc. lowest stock price was $244.52 and its highest was $298.45 in the past 12 months.
What is Labcorp Holdings Inc.’s market cap?
Labcorp Holdings Inc.’s market cap is $23.08B.
When is Labcorp Holdings Inc.’s upcoming earnings report date?
Labcorp Holdings Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 6 days.
How were Labcorp Holdings Inc.’s earnings last quarter?
Labcorp Holdings Inc. released its earnings results on Apr 30, 2026. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $4.11 by $0.14.
Is Labcorp Holdings Inc. overvalued?
According to Wall Street analysts Labcorp Holdings Inc.’s price is currently Undervalued.
Does Labcorp Holdings Inc. pay dividends?
Labcorp Holdings Inc. pays a Quarterly dividend of $0.72 which represents an annual dividend yield of 0.99%. See more information on Labcorp Holdings Inc. dividends here
What is Labcorp Holdings Inc.’s EPS estimate?
Labcorp Holdings Inc.’s EPS estimate is 4.78.
How many shares outstanding does Labcorp Holdings Inc. have?
Labcorp Holdings Inc. has 82,000,000 shares outstanding.
What happened to Labcorp Holdings Inc.’s price movement after its last earnings report?
Labcorp Holdings Inc. reported an EPS of $4.25 in its last earnings report, beating expectations of $4.11. Following the earnings report the stock price went down -0.132%.
Which hedge fund is a major shareholder of Labcorp Holdings Inc.?
Currently, no hedge funds are holding shares in LH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Labcorp Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$313.43 (15.79% Upside)
$313.43 (15.79% Upside)
Blogger Sentiment
Bullish
LH Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 60.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 7.6%
Last 30 Days ▲ 7.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.83%
12-Months-Change
Fundamentals
Return on Equity
0.99%
Trailing 12-Months
Asset Growth
8.43%
Trailing 12-Months
Company Description
Labcorp Holdings Inc.
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
LH Revenue Breakdown
77.96% Dx
22.21% BLS
-0.16% Intercompany eliminations

LH Stock 12 Month Forecast
Average Price Target
$313.43
▲(15.79% Upside)
Technical Analysis
Ownership Overview
0.32% Insiders
32.43% Mutual Funds
2.60% Other Institutional Investors
37.82% Public Companies and
Individual Investors









